Related Experiment Video
Updated: Jun 26, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
Individualized approaches to pediatric chronic insomnia: Advancing precision medicine in sleep disorders
Oliviero Bruni1, Marco Angriman2, Silvia Miano3
1Developmental and Social Psychology, Sapienza University of Rome, Via dei Marsi 78, 00185, Rome, Italy.
Insights
Chronic insomnia presents differently across age groups, from behavioral issues in infants to sleep-onset problems in school-aged children and adolescents. Understanding these age-related changes can lead to personalized treatments for insomnia.
Area of Science:
- Neuroscience
- Developmental Psychology
- Sleep Medicine
Background:
- Chronic insomnia manifestations vary significantly with age.
- Distinct clinical presentations suggest diverse phenotypes and potential neurotransmitter involvement.
- Genetic factors may influence persistent insomnia and inform treatment strategies.
Purpose of the Study:
- To analyze age-related changes in chronic insomnia manifestations.
- To explore potential phenotypes and neurobiological underpinnings of insomnia across development.
- To inform precision-based treatment approaches for pediatric and adolescent insomnia.
Main Methods:
- Review of clinical presentations of insomnia across different developmental stages (infancy, childhood, adolescence).
- Consideration of genetic studies on pleiotropy and polygenicity.
- Analysis of sleep architecture, circadian rhythms, and homeostatic processes in adolescents.
Main Results:
- Behavioral insomnia is common in young children, responding to behavioral interventions.
- Sleep-onset insomnia, anxiety, and poor sleep hygiene characterize school-age children.
- Adolescent insomnia involves delayed sleep onset, hyperarousal, and altered sleep architecture.
Conclusions:
- Age-specific assessment of insomnia is crucial for accurate diagnosis.
- Subtyping insomnia based on developmental stage and presentation can guide tailored treatments.
- Understanding neurobiological and familial factors may enhance treatment selection for pediatric insomnia.
Abstract:
The manifestations of chronic insomnia undergo age-related changes. In younger infants and children, behavioral insomnia emerges as the most prevalent form and typically responds to behavioral interventions. However, distinct clusters of clinical presentations suggest the presence of various phenotypes, potentially implicating the primary involvement of specific neurotransmitters. These conceptualizations, coupled with genetic studies on pleiotropy and polygenicity, may aid in identifying individuals at risk of persistent insomnia into adulthood and shed light on novel treatment options. In school-age children, the predominant presentation is sleep-onset insomnia, often linked with nighttime fears, anxiety symptoms, poor sleep hygiene, limit-setting issues, and inadequate sleep duration. The manifestations of insomnia in adolescence correlate with the profound changes occurring in sleep architecture, circadian rhythms, and homeostatic processes. The primary symptoms during adolescence include delayed sleep onset, sleep misperception, persistent negative thoughts about sleep, and physiological hyperarousal-paralleling features observed in adult insomnia. An approach centered on distinct presentations may provide a framework for precision-based treatment options. Enhanced comprehension of insomnia's manifestations across diverse developmental stages can facilitate accurate assessment. Efforts to subtype insomnia in childhood align with this objective, potentially guiding the selection of appropriate treatments tailored to individual neurobiological, clinical, and familial features.
Related Concept Videos
Management of Insomnia
Insomnia
Multiple factors contribute...
Narcolepsy
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:

